Literature DB >> 1451729

The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers.

A Munafo1, T Buclin, D Tuto, J Biollaz.   

Abstract

We have studied the effects of quinidine on ECG intervals and on the pharmacokinetics of flecainide and its two metabolites in 6 healthy men in an open randomized crossover study. Flecainide acetate (150 mg) was given as a constant rate i.v. infusion over 30 min. Quinidine (50 mg orally), given the previous evening, did not change the volume of distribution of flecainide (7.9 vs 7.4 l.kg-1), but significantly increased its half-life (8.8 vs 10.7 h). This was attributable to a reduction in total clearance (10.6 vs 8.1 ml.min-1 x kg-1), most of it being accounted for by a reduction in non-renal clearance (7.2 vs 5.2 ml.min-1 x kg-1). The excretion of the metabolites of flecainide over 48 h was significantly reduced. These findings suggest that quinidine inhibits the first step of flecainide metabolism, although it may also reduce its renal clearance, but to a lesser extent (3.5 vs 2.9 ml.min-1 x kg-1). The effects of flecainide on ECG intervals were not altered by quinidine. Thus, quinidine tends to shift extensive metabolizer status for flecainide towards poor metabolizer status and may also alter its renal excretion.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1451729     DOI: 10.1007/bf02220625

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

1.  Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH.

Authors:  A S Gross; G Mikus; C Fischer; M Eichelbaum
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Interaction of digoxin with quinine.

Authors:  J K Aronson; J G Carver
Journal:  Lancet       Date:  1981-06-27       Impact factor: 79.321

3.  The two-period cross-over clinical trial.

Authors:  M Hills; P Armitage
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

4.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1989-08-10       Impact factor: 91.245

5.  Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo.

Authors:  W E Haefeli; M J Bargetzi; F Follath; U A Meyer
Journal:  J Cardiovasc Pharmacol       Date:  1990-05       Impact factor: 3.105

6.  Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype.

Authors:  A S Gross; G Mikus; C Fischer; R Hertrampf; U Gundert-Remy; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

7.  Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation.

Authors:  B Schmid; J Bircher; R Preisig; A Küpfer
Journal:  Clin Pharmacol Ther       Date:  1985-12       Impact factor: 6.875

8.  Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism.

Authors:  C Funck-Brentano; J Turgeon; R L Woosley; D M Roden
Journal:  J Pharmacol Exp Ther       Date:  1989-04       Impact factor: 4.030

9.  Pharmacodynamics and side effects of flecainide acetate.

Authors:  D M Salerno; G Granrud; P Sharkey; J Krejci; T Larson; D Erlien; D Berry; M Hodges
Journal:  Clin Pharmacol Ther       Date:  1986-07       Impact factor: 6.875

10.  Sparteine oxidation is practically abolished in quinidine-treated patients.

Authors:  R Brinn; K Brøsen; L F Gram; T Haghfelt; S V Otton
Journal:  Br J Clin Pharmacol       Date:  1986-08       Impact factor: 4.335

View more
  2 in total

1.  Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects.

Authors:  Kyoung Soo Lim; Joo-Youn Cho; In-Jin Jang; Bo-Hyung Kim; JaeWoo Kim; Ji-Young Jeon; Yu-Mi Tae; SoJeong Yi; SoYoung Eum; Sang-Goo Shin; Kyung-Sang Yu
Journal:  Br J Clin Pharmacol       Date:  2008-07-24       Impact factor: 4.335

Review 2.  Antiarrhythmic agents: drug interactions of clinical significance.

Authors:  T C Trujillo; P E Nolan
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.